BIOCON

BIOCON

approved_indications FDA Approved Biologics and Pending Applications

Fulphila®

pegfilgrastim-jmdb
aBL 761075

Ogivri

trastuzumab-dkst
aBL 761074

approved_indications Approved Foreign Follow-On Biologics / Biosimilars

Biosimilars Approved In Canada

Ogivri (trastuzumab) (Mylan / Biocon) (May-2019)

Biosimilars Approved In The E.U.

Ogivri (trastuzumab) (Mylan / Biocon) (December-2018)Semglee (insulin glargine recombinant) (Mylan / Biocon) (March-2018)

Biosimilars Approved In Australia

Ogivri (trastuzumab) (Mylan / Biocon) (December-2018) Semglee (insulin glargine recombinant) (Mylan / Biocon) (March-2018)

Biosimilars Approved In Japan

Insulin glargine BS (insulin glargine recombinant) (Biocon / Fujifilm Pharma) (March-2016)

approved_indications Inter Partes Review Proceedings

GENENTECH CABILLYIPR2016-00710
LANTUS / LANTUS SOLOSTARIPR2017-01526
IPR2017-01528
IPR2018-01670
IPR2018-01675
IPR2018-01676
IPR2018-01677
IPR2018-01678
IPR2018-01679
IPR2018-01680
IPR2018-01682
IPR2018-01684
IPR2018-01696
IPR2019-00122

related articles Related News Articles

Spotlight On: Lantus® / Lantus® SoloSTAR® (insulin glargine recombinant) / Basaglar® (insulin glargine) April Breyer Menon; Damineh Morsali; Corinne E. Atton; Robert S. Schwartz, Ph.D. November 30, 2019
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – May 2019 April Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. June 6, 2019
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – April 2019 April Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. May 7, 2019
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – November 2018 April M. Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. December 11, 2018
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – October 2018 April M. Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. November 12, 2018
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – September 2018 April M. Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. October 6, 2018
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – June 2018 April M. Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. July 6, 2018
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – December 2017 April M. Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. January 8, 2018
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – July 2017 April M. Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. July 26, 2017

Methodology

Information contained in the Venable Fitzpatrick BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website (www.fda.gov). Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website (www.fda.gov). Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics graphics are compiled from information contained in the Venable Fitzpatrick BiologicsHQ database.

Disclaimer

The individuals who maintain this site work for Venable LLP. The information, comments and links posted on this site do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. For legal advice, contact an attorney at Venable LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. If you send any information, documents or materials to the site, you give permission for the author to include them on or in the site. No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the author.

Subscribe for Future Updates

captcha